Nutrient-Stimulated Hormone Therapies in Heart Failure: Targeting Cardiometabolic Burden Beyond Weight Reduction

Published May 11, 2026International journal of heart failure

Hormone Treatments Activated by Nutrients for Heart Failure That Address Metabolism Beyond Weight Loss

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Page updated May 12, 2026

Abstract

Nutrient-Stimulated Hormone (NuSH) therapies may offer surgical-magnitude weight loss and improve outcomes in heart failure with preserved ejection fraction (HFpEF).

NuSH therapies, such as glucagon-like peptide-1 receptor agonists, have shifted the treatment paradigm for obesity and heart failure.
Evidence from the STEP-HFpEF and SUMMIT trials indicates that these therapies can restore functional capacity and reduce severe clinical outcomes.
There is ongoing uncertainty regarding the safety of NuSH therapies in heart failure with reduced ejection fraction (HFrEF), particularly related to heart rhythm effects.
Future directions include addressing sarcopenic obesity and developing biomarker-guided treatment protocols.

AI simplified

The intersection of obesity and heart failure (HF) represents a growing epidemic characterized by a distinct cardiometabolic phenotype. Historically, management has been hamstrung by a significant therapeutic gap: lifestyle interventions often fail to overcome metabolic inertia, yielding negligible weight reduction, while bariatric surgery remains limited by invasiveness. The emergence of Nutrient-Stimulated Hormone (NuSH) therapies, including glucagon-like peptide-1 receptor agonists, has revolutionized this landscape. This review delineates the paradigm shift driven by these agents, which act as a "medical bypass" offering surgical-magnitude weight loss and broad pleiotropic cardioprotection. We analyze pivotal evidence from the STEP-HFpEF and SUMMIT trials, demonstrating that NuSH therapies have established a new standard of care in heart failure with preserved ejection fraction (HFpEF) by not only restoring functional capacity but also significantly reducing hard clinical endpoints. Conversely, we navigate the uncertainty surrounding heart failure with reduced ejection fraction (HFrEF), where historical safety signals regarding chronotropic effects and arrhythmias necessitate a cautious, precision-based approach. Finally, we discuss critical future frontiers, emphasizing the "muscle imperative" to mitigate sarcopenic obesity and the need for biomarker-guided protocols. NuSH therapies have evolved from metabolic tools into essential disease-modifying pillars, necessitating a fundamental recalibration of clinical practice to target the metabolic root of HF.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

Nutrient-Stimulated Hormone Therapies in Heart Failure: Targeting Cardiometabolic Burden Beyond Weight Reduction

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief